Goldman Sachs Initiates Coverage On Horizon Therapeutics with Neutral Rating, Announces $35 Price Target

Goldman Sachs analyst Graig Suvannavejh initiates coverage on Horizon Therapeutics (NASDAQ:HZNP) with a Neutral rating and a $35 price target.

Benzinga · 01/08/2020 11:41

Goldman Sachs analyst Graig Suvannavejh initiates coverage on Horizon Therapeutics (NASDAQ:HZNP) with a Neutral rating and a $35 price target.